Figure 7.
Inhibiting ERK3/MK5 pathway in obese mice promotes energy dissipation and prevents further body weight gain. (A–E) Bodyweight evolution (A), energy expenditure (B), expression of thermogenic genes (C), glucose tolerance test (D), and insulin tolerance test (E) of mice with inducible deletion of Erk3 (Erk3Ind.Adipo.Δ/Δ) and control animals fed HFD upon administration of tamoxifen at indicated time point. (F) Glycerol release in circulation after injection of β-agonist (CL316243) for indicated times in BL6/J mice that have been orally administered with GLPG0259 inhibitor (10 mg/kg) or vehicle control for one consecutive week (n = 5). (G) Relative Atgl expression in SubWAT from GLPG0259 administered mice and their respective vehicle control mice (n = 5). (H) Proposed model of action of the β-adrenergic-induced ERK3/MK5/FOXO1 pathway. Data are presented as average ± SEM. (**) P ≤ 0.005; (***) P ≤ 0.01.